B

Bioton SA
WSE:BIO

Watchlist Manager
Bioton SA
WSE:BIO
Watchlist
Price: 2.81 PLN -3.77% Market Closed
Market Cap: 241.3m PLN
Have any thoughts about
Bioton SA?
Write Note

Operating Margin
Bioton SA

1.1%
Current
8%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
1.1%
=
Operating Profit
1.9m
/
Revenue
177.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
PL
Bioton SA
WSE:BIO
241.3m PLN
1%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
317.9B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.7B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.9B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country PL
Market Cap 241.3m PLN
Operating Margin
1%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 317.9B USD
Operating Margin
28%
Country US
Market Cap 141.7B USD
Operating Margin
19%
Country US
Market Cap 117.1B USD
Operating Margin
38%
Country US
Market Cap 104.9B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.4B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Bioton SA
Glance View

Market Cap
241.3m PLN
Industry
Biotechnology

BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

BIO Intrinsic Value
2.83 PLN
Undervaluation 1%
Intrinsic Value
Price
B

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
1.1%
=
Operating Profit
1.9m
/
Revenue
177.6m
What is the Operating Margin of Bioton SA?

Based on Bioton SA's most recent financial statements, the company has Operating Margin of 1.1%.